Table 3 Treatment-related adverse events occurring in ≥ 10% of patients with locally advanced or metastatic bladder cancer in either group
|  | TGC (n = 14) | GC (n = 17) | ||
|---|---|---|---|---|
Any grade | Grade ≥ 3 | Any grade | Grade ≥ 3 | |
Patients with ≥ 1 AEs, n (%) | 14 (100) | 5 (35.7) | 17 (100) | 4 (23.5) |
Anemia | 8 (57.1) | 3 (21.4) | 8 (47.1) | 2 (11.8) |
Pyrexia | 5 (35.7) | 1 (7.1) | 4 (23.5) | 2 (11.8) |
Decreased WBC count | 5 (35.7) | 2 (14.3) | 5 (29.4) | 2 (11.8) |
Decreased neutrophil count | 4 (28.6) | 2 (14.3) | 3 (17.6) | 1 (5.9) |
Decreased platelet count | 4 (28.6) | 2 (14.3) | 3 (17.6) | 1 (5.9) |
Increased ALT | 2 (14.3) | 0 | 2 (11.8) | 0 |
Increased AST | 2 (14.3) | 0 | 2 (11.8) | 0 |
Fatigue | 4 (28.6) | 1 (7.1) | 4 (23.5) | 1 (5.9) |
Decreased appetite | 8 (57.1) | 4 (28.6) | 5 (29.4) | 2 (11.8) |
Rash | 2 (14.3) | 0 | 2 (11.8) | 0 |
Nausea/vomiting | 7 (50.0) | 4 (28.6) | 6 (35.3) | 3 (17.6) |
Thyroid disorders | 6 (42.9) | 3 (21.4) | 0 | 0 |
Increased blood creatinine | 4 (28.6) | 2 (14.3) | 5 (29.4) | 3 (17.6) |